Valeant Pharmaceuticals Announces Planned Management Departure - KAIT-Jonesboro, AR-News, weather, sports

Valeant Pharmaceuticals Announces Planned Management Departure

  • Most Popular StoriesMost Popular StoriesMore>>

  • 77-year-old questioned, defended as true Marine after NFL player takes his photo

    77-year-old questioned, defended as true Marine after NFL player takes his photo

    Tuesday, July 22 2014 6:15 AM EDT2014-07-22 10:15:36 GMT
    (WMC) - It was a story that made its rounds on social media. On a recent flight DeAngelo Williams, Mid-Southerner and running back for the Carolina Panthers, gave his first-class plane seat to a 77-year-old
    Family members are upset and hurt that their relative, James Wesley Bolden, is being called a liar and "a fake."
  • Cracking the pricing code: Price tag secrets will save you money

    Cracking the pricing code: Price tag secrets will save you money

    Friday, July 18 2014 12:27 PM EDT2014-07-18 16:27:37 GMT
    You see what you think is important on price tags; "half off," "clearance," "big discounts." Turns out, you may be looking right past the most important thing on the tag.
    You see what you think is important on price tags; "half off," "clearance," "big discounts." Turns out, you may be looking right past the most important thing on the tag.
  • UPDATE: Police release details on fatal wreck near Trumann

    UPDATE: Police release details on fatal wreck near Trumann

    Monday, July 21 2014 4:15 PM EDT2014-07-21 20:15:10 GMT
    Arkansas State Police say two people died Monday morning when their vehicles collided on U.S. Highway 63 near Trumann. 
    Arkansas State Police say two people died Monday morning when their vehicles collided on U.S. Highway 63 near Trumann. 

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Valeant Pharmaceuticals International, Inc.

LAVAL, Quebec, June 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the Company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant to Nestlé S.A.  Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma. 

"The Board of Directors and I appreciate the significant contributions Ryan has made during his time with Valeant, especially his efforts through the Medicis integration and his tireless dedication with the aesthetic and dermatology communities," said J. Michael Pearson, chairman and chief executive officer.  "As a clear testament to the performance of Valeant's aesthetic commercial team, Galderma is in discussions with the injectable team to discuss long-term opportunities.  Although his leadership will be missed, the company has created and developed a strong management team and I am confident Ryan will assist us successfully through this transition period."

"The last six years at Valeant has been an extraordinary experience," said Ryan Weldon.  "It has been a privilege to work with Mike, my fellow Valeant employees, and the Board on this journey."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology  and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding the long-term opportunities at Galderma for the aesthetics team. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact Information:
Valeant Pharmaceuticals:
Investors:                                                                   
Laurie W. Little
Valeant Pharmaceuticals International, Inc.                                                       
949-461-6002                                                             
laurie.little@valeant.com                                           

Media:
Renee E. Soto/Meghan Gavigan
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com / mgavigan@sardverb.com

Valeant Pharmaceuticals International, Inc.

 Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

472 Craighead Co. 766
Jonesboro, AR 72401
(870) 931-8888

FCC Public File
publicfile@kait8.com
(870) 336-1816
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KAIT. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.